🔔📣📢 RADIOSA full paper is finally out! Read our publication now online on The Lancet Oncology! Randomised trial in the metachronous oligomets hormone-sensitive PCa setting reporting improved clinical PFS with the combination of SBRT and a short course of ADT!

Staging EBUS and the new TNM staging system. Offering correct treatment options to patient is dependent on accurate staging. #BTOG25

Explore the latest in reirradiation – a game-changer in cancer treatment at our CPD-accredited webinar on March 27 at 7 PM. Gain insights, ask questions, and connect with leading experts. Don’t miss out! Register today👉🏽 nuvi.me/u00ywc

#ESTRO25 kick off! Morning Vienna!

Encouraging SABR data for high-risk PCa! (pelvis included!) #GU #ESTRO25

The kind of data we need in macroscopic prostate bed relapse! Promising ADT-Sparing SABR! Kudos to all authors! #ESTOR25

Kudos RadioterapiaHM !!!

🚨10y results of HYPO RT PC at #ESTRO25 Hypofractionated #prostatecancer RT (42,7/7) vs conv fractionated RT 1. Non inferior for FFS (even better?) 2. Similar bPFS, DMFS, ADT use, OS 3. Similar GU/GI tox (except transient flare at 1y for UHF)

SBRT + 💊 in oligomets: 🧍‍♂️2294 pts | 🫁, breast, prostate, colorectal ⚠️Grade 3+ AEs: 1.5% ✅ SBRT Safe with systemic tx! #SBRT #OligoCare #ESTRO25 EORTC ESTRO Ciro Franzese

That’s a wrap #ESTRO25! ⁦ESTRO⁩ Proud to see the hard work&commitement of the ⁦⁦⁦GenesisCareUK⁩ to providing experience-based evidence in the pursuit of clinical improvement! Here our contribution to #SMART using MRIdian on #upperGI linkedin.com/posts/elena-mo…

Proud to see EMERALD Trial findings presented at #ESTRO2025 by Dr. Somnath Mukherjee! Watch this short video from James Good to discover how MR-guided SABR is transforming pancreatic cancer treatment 🎥 Click to download ESTRO presentation 👉🏽 bit.ly/4d4MHbC

📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence. 🚨Meta-analysis of 43 studies (n=8,119) ⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats Declan Murphy marlon perera + team European Association of Urology (EAU)! ➡️link shorturl.at/unfn5

🧾 New Cheat Sheet on Prostate Cancer Treatment by Stage 🔹 Low-risk: Active surveillance; avoid ADT 🔹 Intermediate-risk: Surgery or RT; ADT case-based 🔹 High-risk: Surgery/RT + long-term ADT #EAUguidelines #ProstateCancer Download Cheat Sheet here: uroweb.org/guidelines/pro…

📢The experience from RadioterapiaHM is just out!! 🎯Clinician- And Patient-Reported Outcomes Of Stereotactic Ablative Radiotherapy For High-Risk Prostate Cancer #radonc #pcsm #SABR practicalradonc.org/article/S1879-…

📢 New in European Urology Amar Kishan et al: 🎯 MRI-guided SBRT for prostate cancer significantly reduces late GU and GI toxicity vs CT-guided SBRT at 2 years! 🔬 In the MIRAGE RCT, MRI guidance with tighter margins (2 mm) halved GU toxicity (27% vs 51%) and markedly reduced

MR- vs CT-guided: nearly half GU toxicity!!💥💥💥

High-risk prostate cancer patients had a significantly lower incidence of distant metastasis with a radiotherapy-based treatment strategy than with a prostatectomy-based treatment #radonc #pcsm sciencedirect.com/science/articl…